The approval was supported by data from two phase 3 studies that evaluated Caplyta as monotherapy and adjunctive therapy with lithium or valproate in adults with bipolar depression. The Food and Drug ...

The US Food and Drug Administration (FDA) has expanded approval of lumateperone (Caplyta) to include treatment of adults with depressive episodes associated with bipolar I and II disorder, as ...

CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or ...

Intra-Cellular rolled out its first bipolar ad campaign for Caplyta after nabbing a new FDA approval for the condition at the end of last year. This isn’t Caplyta's first DTC rodeo, though; back in ...

The FDA approved lumateperone (Caplyta) for bipolar-related depressive episodes, Intra-Cellular Therapies announced Monday. The atypical antipsychotic gained an indication for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Caplyta reduced depression symptoms in patients with major depressive episodes linked to bipolar I and bipolar ...

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

Intra-Cellular Therapies fought hard to secure its antipsychotic Caplyta an initial FDA nod in schizophrenia in late 2019. Early sales in the first half of 2020 were only in the single-digit millions, ...

(BPT) – From the outside, Teresa’s life looked great. She had a healthy family and lasting friendships. However, she didn’t feel great. She had periods of panic attacks, trouble sleeping, constant ...